Bioliberty Raises $10.2M Funding For Soft Robotic Glove Medtech Innovation

The round includes an $8.2 million Series A, highlighted by a $4 million investment from the Scottish National Investment Bank, alongside participation from existing investors Archangels, Eos Advisory, Old College Capital and Hanna Capital SEZC, as well as new investor Conduit Connect. This follows a $2 million pre-Series A round in mid-2025 from the existing investor group.

As part of the funding, Russell Bailey, PT, FACHE, President of Lifepoint Rehabilitation, and Dana Prommel Strauss, DPT, Lead Director of Public Policy and Government Affairs at CVS Health, have joined Bioliberty’s Board of Directors.

Read Also - Female-Led VC VitaminºC Closes First €18M For Debut Climate Fund

The company plans to use the capital to advance the development and U.S. commercialization of its Lifehub Clinic platform.

Co-founded in 2020 by Rowan Armstrong (CEO), Conan Bradley (Chief Design), Ross O’Hanlon (CTO) and Shea Quinn (COO), Bioliberty developed the Lifeglov, a soft robotic glove designed to rehabilitate both hand closing and opening strength.

The device tracks key metrics of upper limb mobility and monitors patient progress throughout therapy.

The company’s technology delivers targeted rehabilitation while analyzing functional movement data to guide recovery and support discharge planning.

About Bioliberty

Bioliberty creates advanced rehabilitation technologies, including the Lifeglov soft robotic glove aiming to help people recover from mobility-limiting injuries or conditions. Its solutions track progress, deliver therapy and provide data-driven insights to restore independence and support effective recovery and discharge planning.